Wegovy FlexTouch 0.25mg: What to Expect From the Starting Dose

Step 1, Understanding what the 0.25mg pen actually does

Semaglutide acts on GLP-1 receptors in the brain and gut, slowing how quickly the stomach empties and reducing appetite signals. At 0.25mg, the pharmacological effect on weight is minimal. That is deliberate. The body needs time to adjust to a new hormonal signal, and introducing it at a low level significantly reduces the intensity of nausea, vomiting and digestive discomfort that can occur at higher doses.

Think of it less as a treatment pen and more as an acclimatisation pen. The 0.25mg starting dose exists specifically to make the dose escalation ahead of it more tolerable, not to produce meaningful weight loss in week one or two. Most people who feel frustrated that nothing dramatic is happening at this stage are on track, this is normal and expected.

The NHS medicines guidance on semaglutide confirms that 0.25mg is a starting dose only, with titration planned from the outset. You can read the full patient-level information on the NHS semaglutide medicine page.

Step 2, Using the FlexTouch pen correctly from week one

The Wegovy FlexTouch is a pre-filled, pre-set injection pen. There is no dial to turn and no dose to select, at 0.25mg the pen is already calibrated for you. Each pen contains four doses, one for each week of the starting month. You inject once weekly, on the same day each week, rotating between three possible sites: the abdomen, the outer thigh, or the upper arm.

The injection is subcutaneous, under the skin, not into a muscle. Clean the site before injecting. For detailed administration steps, the Patient Information Leaflet that arrives with your pen is the definitive source; your prescriber can also walk you through technique during the consultation process. If you have questions about the pen format before committing to treatment, the Wegovy FlexTouch injection page covers the pen's mechanics in more detail.

Storage matters too. Wegovy pens must be kept refrigerated at 2–8°C until use. The exact room-temperature window after first use is stated in the leaflet, always follow that, not a general figure quoted online. One practical note: keep the pen in the fridge door rather than the back of the shelf, where it risks freezing against the cooling element.

Step 3, Managing side effects during the lowest dose

Even at 0.25mg, some people experience nausea, loose stools, constipation or indigestion. These are the most commonly reported effects in clinical trials and in everyday use. They tend to be mild at this starting level and settle for most people within the first couple of weeks. Eating smaller portions, avoiding high-fat meals and staying well-hydrated all help.

Serious effects are rare but worth knowing. Seek urgent medical attention for severe, persistent stomach pain that spreads to your back, this can be a sign of pancreatitis, which the MHRA flagged as an infrequent but serious risk in its January 2026 Drug Safety Update for GLP-1 medicines. Also seek help for any signs of a severe allergic reaction. For non-urgent questions between doses, our support team is available seven days a week.

You can report any suspected side effect directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Step 4 (What happens after the first four weeks

After four weeks on 0.25mg, the standard next step is 0.5mg) again for four weeks, then 1.0mg, 1.7mg, and finally 2.4mg as the standard maintenance dose. The full titration schedule and what each stage involves is covered on the Wegovy doses page. A higher 7.2mg dose received MHRA approval in April 2026 for adults with a BMI of 30 or above, available as a dedicated single-dose pen.

No dose increase happens without a clinical review. At nume, a GPhC-registered prescriber reads your repeat consultation before any higher-strength pen is dispatched, your progress, any side effects and your current health picture are all considered. That review happens the same working day as your request if submitted before 12pm, so there is no gap in your supply waiting on a human decision.

If you are weighing up whether Wegovy is right for your situation, the Wegovy overview covers eligibility, how results compare across doses and the full cost picture. For a broader look at injection and tablet options, the treatment page is the right starting point, and where a free consultation begins if you are ready to speak to a prescriber.

People do sometimes ask whether early results at 0.25mg predict their eventual outcome. The honest answer is: not really. The 0.25mg results page addresses this directly, separating what the evidence shows from what the starter dose is actually designed to do.